

Candriam Equities L Europe Innovation

Market Overview

Whilst 2024 was an outstanding year in terms of global stock market performance, there was no year-end rally in December. Global equity markets were down mainly because the FED indicated that going forward, the pace of rate cuts would slow down, as the economy remains strong and inflation is stable rather than coming off further. Equity markets, that were mainly driven by rate cuts, slowing inflation and resilient economic growth over the course of 2024, gave up a bit of their excellent 2024 performance. As the presidential inauguration in the US is coming closer, investors also start to take into account some uncertainty about tax cuts, tariffs, an potential immigration stop, reshoring, expansionary fiscal policy and deregulation. There is still no concrete evidence that President Trumps will be able to translate his campaign promises into effective actions.

In Europe, the absence of reliable measures of slack makes it difficult for policymakers to weigh the relative importance of weak demand and supply performance. The lack of effective metrics breeds caution, and places greater weight on slow-moving trends in wage and service price inflation. The shift in risk bias in the face of a recent troubling loss of growth momentum has thus remained incremental. In all, the gradualism expressed by European central banks this month does not dampen the market's confidence that they will ultimately lower policy rates significantly more than the FOMC.

Portfolio Highlights

European equities closed the month slightly lower driven by rate-related developments. The European Central Bank implemented another rate cut in December but maintained a more hawkish tone than expected. France faced significant political upheaval after a successful no-confidence vote ousted the government of Michel Barnier, putting pressure on French assets. The fund slightly outperformed its benchmark in December.

Our key positive contributors were Hexagon (announcement of a highly regarded new CEO), Finacobank and bioMérieux.

On the other hand, our main performance detractors were Carl Zeiss Meditec (decent Q4 reported, but very cautious guidance for 2025), DSM, and Spirax.

During the month, we took some profit on good 2024 performers such as Inditex and EssilorLuxottica where valuation appeared more stretched. We increased Amadeus and Symrise.

Fund Outlook

The environment should be more favourable to our portfolio given the ongoing rate-cutting cycle from the ECB, which should enable Quality / Growth companies to benefit from better valuation metrics and lower financing conditions. We are confident that long-term rates will not increase in Europe (given low GDP growth and inflation), despite a likely different trajectory in the US following the Trump victory. In addition, the supply-chain normalization should support B2B suppliers that suffered from a long destocking phase.

Lastly, the stimulus plan in China will be positive for some companies in the portfolio (especially within Healthcare equipment), although measures still need to be detailed. We still think that cyclical sectors (Industrials, Consumer Discretionary and Financials) are expensive. However, some European cyclical names with high US exposure, especially within Industrials, will benefit from Donald Trump's upcoming tax cuts. On the other hand, other names (within Automobiles for instance) will be hit by higher US tariffs on European products.

The risk of higher US tariffs is limited because the vast majority of goods sold by European companies in the US are manufactured directly on American soil, and not subject to customs. The damage from higher tariffs would be significant for only a handful of sectors with European production, such as luxury goods and automobiles. For 2025, in line with our soft-landing scenario of the global economy, we expect Quality / Growth stocks (and particularly Innovative companies) to outperform.

This marketing communication is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.

Warning: Past performance of a given financial instrument or index or an investment service or strategy, or simulations of past performance, or forecasts of future performance does not predict future returns. Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change.

In respect to money market funds, please be aware that an investment in a fund is different from an investment in deposits and that the investment's principal is capable of fluctuation. The fund does not rely on external support for guaranteeing its liquidity or stabilizing its NAV per unit or share. The risk of loss of the principal is borne by the investor.

Candriam consistently recommends investors to consult via our website www.candriam.com the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value ("NAV") of the funds. Investor rights and complaints procedure, are accessible on Candriam's dedicated regulatory webpages <https://www.candriam.com/en/professional/legal-and-disclaimer-candriam/regulatory-information/>. This information is available either in English or in local languages for each country where the fund's marketing is approved. According to the applicable laws and regulations, Candriam may decide to terminate the arrangements made for the marketing of a relevant fund at any time.

Information on sustainability-related aspects: the information on sustainability-related aspects contained in this communication are available on Candriam webpage <https://www.candriam.com/en/professional/market-insights/sfdr/>. The decision to invest in the promoted product should take into account all the characteristics or objectives of the promoted product as described in its prospectus, or in the information documents which are to be disclosed to investors in accordance with the applicable law.

Notice to investors in Switzerland: The information provided herein does not constitute an offer of financial instruments in Switzerland pursuant to the Swiss Financial Services Act ("FinSA") and its implementing ordinance. This is solely an advertisement pursuant to FinSA and its implementing ordinance for financial instruments.

Swiss representative: CACEIS (Switzerland) SA, Route de Signy 35, CH-1260 Nyon. The legal documents as well as the latest annual and semi-annual financial reports, if any, of the investment funds may be obtained free of charge from the Swiss representative.

Swiss paying agent: CACEIS Bank, Paris, succursale de Nyon/Suisse, Route de Signy, 35, CH-1260 Nyon. Place of performance: Route de Signy 35, CH-1260 Nyon. Place of jurisdiction: Route de Signy 35, CH-1260 Nyon.

Specific information for investors in France: the appointed representative and paying agent in France is CACEIS Bank, Luxembourg Branch, sis 1-3, place Valhubert, 75013 Paris, France. The prospectus, the key investor information, the articles of association or as applicable the management rules as well as the annual and semi-annual reports, each in paper form, are made available free of charge at the representative and paying agent in France.

Specific information for investors in Spain: Candriam Sucursal en España has its registered office at C/ Pedro Teixeira, 8, Edif. Iberia Mart I, planta 4, 28020 Madrid and is registered with the Comisión Nacional del Mercado de Valores (CNMV) as an European Economic Area management company with a branch. CNMV: 233